Is it possible to repair metabolism with slow-release carbohydrates? Shize'an has stepped into the metabolic management field with its compound microalgae active peptide powder, and intends to raise 8 million yuan in financing.

Whole-grain slow-release carbohydrate compound formula for comprehensive metabolic regulation and fat reduction, plans to raise RMB 8 million in financing

I. Market Pain Points:

When the weight loss track is collectively trapped in the collective anxiety of "you can only lose weight by eating less", a dietary therapy repair product featuring "lose weight without hunger" is filling the market gap in metabolic management. The microalgae active peptide compound powder launched by Shize'an (Guangzhou) Food Technology Co., Ltd. repairs the damaged metabolic system through an ordinary food formula, providing a brand-new solution for overweight people who have failed in repeated weight loss and people with sub-healthy metabolism.

II. Project Origin

The project originated from the personal experience of the founder Yang Jinru. Having been overweight since childhood, he tried many mainstream weight loss methods such as hunger diet, exercise weight loss, ketogenic diet, and protein diet, all of which failed due to unbearable strong hunger, and his weight rebounded from 160 jin to 213 jin. With the question of "why can't I lose weight even when I'm extremely hungry", Yang Jinru began to devote himself to studying the metabolic theories of traditional Chinese and Western medicine, tested the effects of different foods on blood sugar and hunger one by one combined with his own physical perception, and finally worked out the core formula for repairing metabolism. He successfully lost nearly 80 jin in 2023 alone, thus officially launching the Shize'an dietary therapy project to improve metabolism. In July 2025, the company was registered to enter the big health food track. At present, the core team of the project consists of founder Yang Jinru and co-founder Yang Shengwang. Yang Jinru graduated from Beijing Institute of Technology, who is fully responsible for R&D, production, product design and personnel training. Yang Shengwang graduated from the Department of National Economic Management of Peking University in 1992, with decades of experience in investment banking and securities, who is in charge of financing and market business. From the conception of the formula to the launch of the product, the project has overcome many challenges such as process realization and test verification. The core difficulty lies in restoring the slow-release effect of the formula design. After cooperating with more than ten OEMs, the stable production process was finally polished, and the first weight-loss product was officially launched on JD platform in February 2026.

III. Animal Experiments and Small-sample Human Tests

Compared with traditional weight-loss foods and GLP-1 weight-loss drugs on the market, Shize'an has distinctive differentiated innovation in technology and product logic. Traditional weight-loss meal replacements take calorie restriction as the core, which essentially requires users to "eat less and go hungry", resulting in poor compliance, muscle loss and weight rebound. GLP-1 drugs are prescription drugs that require injection, have gastrointestinal side effects, are extremely prone to rebound after drug withdrawal, and are only available to people who meet the BMI standard. Shize'an is based on slow-release carbohydrates, compounded with microalgae active peptides and dietary fiber, to repair three core metabolic links simultaneously: it repairs the liver glycogen storage capacity, releases absorbable carbohydrates slowly and continuously for 6 hours, so that the brain will not trigger hunger alarm; it enhances the body's own endogenous GLP-1 secretion and restores the normal satiety signal; it directly improves insulin resistance, and fundamentally breaks the physiological closed loop of "easy to be hungry - eat more - get fat". Finally, four core advantages are realized: no need to starve, keep full all day long, and let the body naturally restore normal appetite; no need for extra exercise, to achieve normal daily weight loss; focus on fat loss, to realize fat loss without muscle loss; with excellent compliance, users can adhere to it for a long time. At present, the product has completed three layers of verification: the in vitro digestion test by Beijing Inspection and Certification Group verified the 6-hour continuous slow-release carbohydrate characteristic; the rat animal experiment of Yike Laboratory showed that after intervention, the insulin resistance index decreased by 57.2%, endogenous GLP-1 secretion increased by 81%, and liver glycogen storage increased by 98.6%, the improvement of six core indicators exceeded the animal experiment results of similar first-line drugs; in the nearly one-year small-sample human test, a total of 9 participants of different occupations lost 229.5 jin in total, the average body fat rate decreased by more than 10%, and all participants reached the fat loss expectation.

IV. Market Space

At present, the domestic metabolic health market has a broad space. Data shows that there are more than 400 million overweight and obese adults in China, 233 million diabetes patients, nearly 400 million people with pre-diabetes, plus more than 450 million people with metabolic syndrome. All these groups share insulin resistance as the core pathological basis, forming a rigid demand of hundreds of millions of people. However, there is an obvious structural gap on the supply side at present: the vast majority of weight management foods still stay in the shallow intervention of "calorie restriction", which cannot solve the rebound problem; GLP-1 drugs have accessibility and safety thresholds, and a large number of people with sub-healthy metabolism who do not meet the BMI medication standards and are afraid of side effects have no suitable products to choose from. Shize'an's food-grade metabolic repair solution just fills this supply gap. Data from iiMedia Research shows that China's meal replacement market is expected to reach 3534.9 billion yuan by 2027, the low GI food market is expected to exceed 800 billion yuan, and the functional food market is expected to reach 4237 billion yuan. The three tracks add up to a scale of hundreds of billions of yuan, and the current industry pattern is scattered, there is no absolute leader, with clear growth space.

V. Compliance Roadmap

According to the plan, the project will be upgraded step by step along the compliance path of "ordinary food → special dietary food → blue hat health food → food for special medical purposes". The current capital demand is RMB 8 million angel round financing, with 8% equity transferred. The funds will be mainly used for offline experience store construction, team building, product compliance registration, scientific research investment and market promotion. In the short term, within 12 months after the angel round funds are in place, the project will launch special dietary food for sports nutrition and energy control, obtain the compliance promotion permission, simultaneously launch the sugar control version of the product and complete the low GI certification, open four flagship experience stores in Beijing, Shanghai, Guangzhou and Shenzhen, and launch the pilot of light asset weight loss camp and outpatient cooperation; in the medium term of 2-3 years, the product matrix will be expanded, differentiated products will be launched for obese teenagers, postpartum mothers and people with four high indicators, complete the blue hat registration and open up the pharmacy channel, start the registration of weight-loss food for special medical purposes, which is expected to fill the domestic gap in this category; in the long term of 3-5 years, complete the registration of food for special medical purposes, establish the highest compliance barrier, cover the experience store network in 100 cities, and sprint to the capitalization goal. The project always adheres to the strategy of "building barriers with high qualifications and achieving scale with ordinary food". The core role of high-level qualifications is to provide trust endorsement for the main business of affordable ordinary food, to achieve large volume and repurchase for the vast majority of people with metabolic problems, and will not narrow the customer group due to qualification upgrading.

VI. Commercialization

At present, the product has completed the initial market verification. After being launched on JD, the total positive rating reaches 100%. Users' high-frequency comments focus on "satiety", "good taste" and "healthy ingredients", with strong willingness to repurchase. Users who participated in the early test generally reported that their hunger was greatly reduced, and the accompanying metabolic problems such as hypertension, hyperlipidemia, hyperuricemia and fatty liver also basically returned to normal levels, many users spontaneously shared their experiences on social platforms. At this stage, the project's comprehensive gross profit margin is about 70%. The business model takes product sales as the core, attracts precise traffic through metabolic popularization content online, completes conversion relying on e-commerce and private domain traffic, lays out flagship experience stores + light asset cooperation network offline, converts users through real experience, and achieves growth relying on word-of-mouth fission. At present, the progress in the private domain is smooth, the consumer experience far exceeds expectations, and mature teams are continuously joining in.

VII. Vision

Talking about the feeling of starting a business, Yang Jinru said that as a victim of obesity for many years, he knows best the pain of repeated weight loss failures, and also knows clearly that what users really need is not a pseudo-solution that "depends on willpower to endure hunger", but a real method that fundamentally solves the hunger problem. "We have taken a very slow step on the road of entrepreneurship, but every step is very solid. From our own trial and error to animal experiments and then to user verification, all conclusions are based on data. Our goal is very simple, that is, to use a simple and affordable dietary therapy solution to help more people troubled by metabolic problems lose weight healthily without hunger, so that metabolic management can change from a medical behavior for a few people to a daily choice that most people can afford."